Compared with SonoVue ® LR-5, Sonazoid ® modified LR-5 has better diagnostic sensitivity for hepatocellular carcinoma: a systematic review and meta-analysis

Jiazhi Cao,Hong Wang,Wenwu Ling
DOI: https://doi.org/10.21037/qims-23-1616
2024-03-31
Quantitative Imaging in Medicine and Surgery
Abstract:Background: The contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) is a standardized system for reporting liver nodules in patients at risk of developing hepatocellular carcinoma (HCC) and is only recommended for pure blood pool agents such as SonoVue<sup>®</sup>. A modified LI-RADS was proposed for Sonazoid<sup>®</sup>, a Kupffer cell-specific contrast agent. This meta-analysis was conducted to compare the diagnostic efficiency of the CEUS LI-RADS for SonoVue<sup>®</sup> and the modified LI-RADS for Sonazoid<sup>®</sup>.Methods: The PubMed, Medline, Web of Science, Embase, and Cochrane Library databases were systematically searched to retrieve studies on the diagnostic efficiency of the CEUS LI-RADS algorithms in diagnosing HCC using SonoVue<sup>®</sup> and/or Sonazoid<sup>®</sup> from January 2016 to June 2023. Histopathology or imaging follow-up served as the reference standards. Only articles published in English on retrospective or prospective studies with full reports were included in the meta-analysis. A bivariate random-effects model was used. Data pooling, meta-regression, and sensitivity analysis were performed for the meta-analysis. Deeks' funnel plot asymmetry test was used to evaluate publication bias, and the QUADAS-2 tool was used to assess the methodological quality of eligible studies.Results: In total, 26 studies comprising 8,495 patients with 9,244 lesions were included in the meta-analysis. The pooled data results for SonoVue<sup>®</sup> LI-RADS category 5 (LR-5) and Sonazoid<sup>®</sup> modified LR-5 were as follows: pooled sensitivity: 0.68 [95% confidence interval (CI): 0.64-0.73, I<sup>2</sup>=89.20%; P&lt;0.01] and 0.82 (95% CI: 0.74-0.87, I<sup>2</sup>=85.39%; P&lt;0.01) (P&lt;0.05); pooled specificity: 0.93 (95% CI: 0.90-0.96, I<sup>2</sup>=86.52%; P&lt;0.01) and 0.86 (95% CI: 0.79-0.91, I<sup>2</sup>=59.91%; P=0.01) (P&lt;0.05); pooled area under the curve (AUC): 0.86 (95% CI: 0.82-0.89) and 0.91 (95% CI: 0.88-0.93) (P&lt;0.05), respectively. The meta-regression analysis revealed that the study design, subject enrollment method, and reference standard contributed to the heterogeneity of SonoVue<sup>®</sup> LR-5, and the number of lesions was a source of heterogeneity for Sonazoid<sup>®</sup> modified LR-5. The diagnostic performance of the LI-RADS category M (LR-M) algorithms of SonoVue<sup>®</sup> and Sonazoid<sup>®</sup> was comparable.Conclusions: The Sonazoid<sup>®</sup> modified LR-5 algorithm had a higher diagnostic sensitivity, lower specificity, and higher AUC than SonoVue<sup>®</sup> LR-5.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?